





CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156



PATIENT NAME	: RAHUL MALHOT	PATIENT ID : RAHUM09109228A	
ACCESSION NO :	0028WB00073	AGE: 30 Years SEX: Male	ABHA NO :
DRAWN :		RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
REFERRING DOCT	OR: SELF		CLIENT PATIENT ID :

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	16.5		13.0 - 17.0	g/dL
METHOD : SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT	5.80	High	4.5 - 5.5	mil/µL
METHOD : ELECTRICAL IMPEDANCE				
WHITE BLOOD CELL (WBC) COUNT	9.60		4.0 - 10.0	thou/µL
METHOD : ELECTRICAL IMPEDANCE				
PLATELET COUNT	303		150 - 410	thou/µL
METHOD : ELECTRICAL IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	50.7	High	40.0 - 50.0	%
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV)	87.4		83.0 - 101.0	fL
METHOD : DERIVED/COULTER PRINCIPLE				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.5		27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.6		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.5	High	11.6 - 14.0	%
METHOD : DERIVED/COULTER PRINCIPLE				
MENTZER INDEX	15.1			
METHOD : CALCULATED PARAMETER				
MEAN PLATELET VOLUME (MPV)	9.5		6.8 - 10.9	fL
METHOD : DERIVED/COULTER PRINCIPLE				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	69		40 - 80	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY				
LYMPHOCYTES	19	Low	20 - 40	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY				
MONOCYTES	8		2.0 - 10.0	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY				
EOSINOPHILS	3		1.0 - 6.0	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY				
BASOPHILS	1		0 - 1	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY				











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd E-368, LGF, Nirman Vihar,Near Nirman Vihar Metro NEW DELHI, 110092 NEW DELHI, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

PATIENT NAME : RAHUL MALHOTRA PATIENT ID : RAHUM09109228A ACCESSION NO : 0028WB00073 AGE : 30 Years SEX : Male ABHA NO : DRAWN : RECEIVED : 25/02/2023 08:06 REPORTED : 27/02/2023 12:12 REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
ABSOLUTE NEUTROPHI		6.70		2.0 - 7.0	thou/µL
METHOD : CALCULATED PAR					
ABSOLUTE LYMPHOCYT		1.90		1.0 - 3.0	thou/µL
METHOD : CALCULATED PAR		0 70			hh / l
ABSOLUTE MONOCYTE		0.70		0.2 - 1.0	thou/µL
METHOD : CALCULATED PAR		0.20			thou /ul
ABSOLUTE EOSINOPHI METHOD : CALCULATED PAR		0.29		0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL (0.10		0.02 - 0.10	thou/µL
METHOD : CALCULATED PAR		0.10		0.02 - 0.10	thou/ µL
NEUTROPHIL LYMPHOC		3.5			
METHOD : CALCULATED PAR		5.5			
ERYTHROCYTE SEDI	MENTATION RATE (ES	R),WHOLE			
BLOOD E.S.R		5		< 15	mm at 1 hr
-	RGREN METHOD BY AUTOMATED			< 15	
GLUCOSE FASTING,F					
FBS (FASTING BLOOD		85		74 - 106	mg/dL
METHOD : HEXOKINASE	JUGAN)	05		/4 - 100	mg/uL
	OGLOBIN(HBA1C), ED	TA WHOLE			
BLOOD					
HBA1C METHOD : HPLC		5.3		Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
ESTIMATED AVERAGE		105.4		< 116.0	mg/dL
		103.4		< 110.0	iiig/uL
GLUCOSE, POST-PRA	•	00			
PPBS(POST PRANDIAL	BLOOD SUGAR)	89		Non-Diabetes 70 - 140	mg/dL
METHOD : HEXOKINASE					
LIPID PROFILE, SER	UM				
CHOLESTEROL, TOTAL		218	High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL

METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE











CLIENT CODE: C000138361

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd E-368, LGF, Nirman Vihar,Near Nirman Vihar Metro NEW DELHI, 110092 NEW DELHI, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in

ABHA NO :

REPORTED :

PATIENT ID:

CLIENT PATIENT ID:

27/02/2023 12:12

PATIENT NAME : RAHUL MALHOTRA

ACCESSION NO : 0028WB00073 AGE : 30 Years SEX : Male TRAWN : RECEIVED : 25/02/2023 08:06

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
TRIGLYCERIDES	123		< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC, END POINT HDL CHOLESTEROL	53		< 40 Low	mg/dL
	55		>/=60 High	ing/ac
METHOD : DIRECT MEASURE POLYMER-POLYANION				
CHOLESTEROL LDL	140	High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
NON HDL CHOLESTEROL	165	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER				<i>.</i>
VERY LOW DENSITY LIPOPROTEIN	24.6		Desirable value : 10 - 35	mg/dL
CHOL/HDL RATIO	4.1		3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	2.6		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
ACCESSION NO : 0028WB0007	3 AGE : 30 Years SEX : Male	ABHA NO :
PATIENT NAME : RAHUL MAL	IOTRA	PATIENT ID : RAHUM09109228A
NEW DELHI 110030 DELHI INDIA 8800465156	Tel : 9: CIN - U	DELHI, INDIA 111591115, Fax : U74899PB1995PLC045956 : wellness.eastdelhi@srl.in

SRL Ltd

NEW DELHI, 110092

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	Risk Category				
Extreme risk group	A.CAD with > 1 feature of high risk group	A.CAD with > 1 feature of high risk group			
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C			
	< or $=$ 50 mg/dl or polyvascular disease				
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	major risk factors or evidence of end organ damage 3.			
	Familial Homozygous Hypercholesterolemi	a			
High Risk 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end					
	organ damage. 3. CKD stage 3B or 4. 4. L	DL >190 mg/dl 5. Extreme of a single risk factor. 6.			
	Coronary Artery Calcium - CAC >300 AU.	7. Lipoprotein a $>= 50 \text{mg/dl}$ 8. Non stenotic carotid			
	plaque				
Moderate Risk	2 major ASCVD risk factors				
Low Risk 0-1 major ASCVD risk factors					
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors					
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females		3. Current Cigarette smoking or tobacco use			
2. Family history of premature ASCVD		4. High blood pressure			
5. Low HDL					
N					


Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)











CLIENT CODE: C000138361

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd E-368, LGF, Nirman Vihar,Near Nirman Vihar Metro NEW DELHI, 110092 NEW DELHI, INDIA Tel : 9111591115, Fax : CIN - 112489981995PI C045956
CIN - U74899PB1995PLC045956
Email : wellness.eastdelhi@srl.in

PATIENT ID:

PATIENT NAME : RAHUL MALHOTRA

ACCESSION NO : 0028WB00073 AGE: 30 Years SEX: Male ABHA NO : RECEIVED : 25/02/2023 08:06 27/02/2023 12:12 DRAWN : **REPORTED** : CLIENT PATIENT ID:

REFERRING DOCTOR : SELF

	Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
--	--------------------	--------------	---------	-------------------------------------

Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group	$\langle OR = 30$	$\langle OR = 60$	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE. SERUM

LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL	0.33		UPTO 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE)				
BILIRUBIN, DIRECT	0.14		0.00 - 0.30	mg/dL
METHOD : DIAZOTIZATION				
BILIRUBIN, INDIRECT	0.19		0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER				
TOTAL PROTEIN	7.9		6.6 - 8.7	g/dL
METHOD : BIURET, SERUM BLANK, ENDPOINT				
ALBUMIN	4.9		3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN				
GLOBULIN	3.0		2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER				
ALBUMIN/GLOBULIN RATIO	1.6		1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	30		0 - 40	U/L
METHOD : UV WITHOUT P5P				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	52	High	0 - 41	U/L
METHOD : UV WITHOUT P5P				
ALKALINE PHOSPHATASE	142	High	40 - 129	U/L
METHOD : PNPP, AMP BUFFER-IFCC				
GAMMA GLUTAMYL TRANSFERASE (GGT)	51		8 - 61	U/L
METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC				
LACTATE DEHYDROGENASE	196		135 - 225	U/L

METHOD : L TO P, IFCC











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156



8800465156	CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in				
PATIENT NAME : RAHUL MALHO	TRA	PATIENT ID : RAHUMOS	109228A		
ACCESSION NO : 0028WB00073	AGE: 30 Years SEX: Male	ABHA NO :			
DRAWN :	RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12			
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :			
Test Report Status <u>Final</u>	Results	Biological Reference Interval U	Inits		
BLOOD UREA NITROGEN (BUN),	SERUM				
BLOOD UREA NITROGEN	11	6 - 20 mg	/dL		
METHOD : UREASE - UV					
CREATININE, SERUM					
CREATININE	0.96	0.70 - 1.20 mg	/dL		
METHOD : ALKALINE PICRATE-KINETIC					
BUN/CREAT RATIO					
BUN/CREAT RATIO	11.46	5.00 - 15.00			
METHOD : CALCULATED PARAMETER					
URIC ACID, SERUM					
URIC ACID	4.7	3.4 - 7.0 mg	/dL		
METHOD : URICASE, COLORIMETRIC					
TOTAL PROTEIN, SERUM					
TOTAL PROTEIN	7.9	6.6 - 8.7 g/c	L		
METHOD : BIURET, SERUM BLANK, ENDPOINT					
ALBUMIN, SERUM					
ALBUMIN	4.9	3.97 - 4.94 g/c	L		
METHOD : BROMOCRESOL GREEN					

GLOBULIN			
GLOBULIN	3.0	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	141	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.40	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	100	98 - 107	mmol/L
METHOD : ISE INDIRECT			











CLIENT CODE : C000138361

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

SRL Ltd
E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro
NEW DELHI, 110092
NEW DELHI, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956
Email : wellness.eastdelhi@srl.in

PATIENT ID:

PATIENT NAME : RAHUL MALHOTRA

<u>Final</u>

0028WB00073 ACCESSION NO : AGE : 30 Years SEX : Male ABHA NO : RECEIVED : 25/02/2023 08:06 REPORTED : 27/02/2023 12:12 DRAWN : REFERRING DOCTOR : SELF CLIENT PATIENT ID: **Test Report Status** Results **Biological Reference Interval** Units

Interpretation(s)

8800465156

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosi
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
ntoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
hiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion c
hlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
epressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
ncreased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
omiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
nellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
yperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
vater intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
icorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
nterferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
yperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anior
nvolves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
purious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
alls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
ng/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignanc
	levels are normal.	(Normal serum chloride)

COLOR	PALE YELLOW	
METHOD : VISUAL		
APPEARANCE	CLEAR	
METHOD : VISUAL		
CHEMICAL EXAMINATION, URINE		
PH	7.5	4.7 - 7.5
METHOD : DOUBLE INDICATOR PRINCIPLE		
SPECIFIC GRAVITY	1.015	1.003 - 1.035
METHOD : PKA CHANGE OF PRETREATED POLYELECTROLYTES		
PROTEIN	DETECTED (TRACE)	NOT DETECTED
METHOD : PROTEIN- ERROR INDICATOR		
GLUCOSE	NOT DETECTED	NOT DETECTED
GLUCOSE METHOD : OXIDASE-PEROXIDASE REACTION	NOT DETECTED	NOT DETECTED
	NOT DETECTED	NOT DETECTED
METHOD : OXIDASE-PEROXIDASE REACTION		











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156



PATIENT NAME : RAHUL MALHOTRA PATIENT ID : RAHUM09109228A ACCESSION NO : 0028WB00073 AGE : 30 Years SEX : Male ABHA NO : DRAWN : RECEIVED : 25/02/2023 08:06 REPORTED : 27/02/2023 12:12 REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN			
BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : DIAZOTIZATION			
UROBILINOGEN	NORMAL	NORMAL	
METHOD : MODIFIED EHRLICH REACTION			
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD : CONVERTION OF NITRATE TO NITRITE			
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
METHOD : ESTERASE HYDROLYSIS ACTIVITY			
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR :	SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
ACCESSION NO : 002	8WB00073	AGE: 30 Years SEX: Male	ABHA NO :
PATIENT NAME : RA	HUL MALHOT	RA	PATIENT ID : RAHUM09109228A
NEW DELHI 110030 DELHI INDIA 8800465156		Tel : 911 CIN - U7	LHI, INDIA .1591115, Fax : '4899PB1995PLC045956 vellness.eastdelhi@srl.in

SRL Ltd

NEW DELHI, 110092

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions			
Proteins	Inflammation or immune illnesses			
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind			
	of kidney impairment			
Glucose	Diabetes or kidney disease			
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst			
Urobilinogen	Liver disease such as hepatitis or cirrhosis			
Blood	Renal or genital disorders/trauma			
Bilirubin	Liver disease			
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases			
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions			
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or			
-	bladder catheters for prolonged periods of time			
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,			
	interaction with Bence-Jones protein			
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases			
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice			
Uric acid	arthritis			
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.			
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis			
HYROID PANEL, SERUM				
3	128.6 80.00 - 200.00			
METHOD : ECLIA				
4	8.12 5.10 - 14.10			
METHOD : ECLIA				

3.230



TSH (ULTRASENSITIVE)

METHOD : ECLIA



ng/dL

µg/dL

µIU/mL

0.270 - 4.200





CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR :	SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
ACCESSION NO : 002	8WB00073	AGE : 30 Years SEX : Male	ABHA NO :
PATIENT NAME : RA		FRA	PATIENT ID : RAHUM09109228A
NEW DELHI 110030 DELHI INDIA 8800465156		Tel : 91 CIN - U	ELHI, INDIA 11591115, Fax : 74899PB1995PLC045956 wellness.eastdelhi@srl.in

SRL Ltd

NEW DELHI, 110092

E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
	_				Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

POSITIVE

RH TYPE

METHOD : COLUMN AGGLUTINATION TECHOLOGY

METHOD : COLUMN AGGLUTINATION TECHOLOGY

XRAY-CHEST











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156



30.0 and Above: Obese

PATIENT NAME: RAHUL MALHOTRA PATIENT ID: RAHUM09109228A 0028WB00073 ACCESSION NO : AGE: 30 Years SEX : Male ABHA NO : RECEIVED : 25/02/2023 08:06 27/02/2023 12:12 DRAWN : **REPORTED** : CLIENT PATIENT ID:

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
»»	BOTH THE LUNG FI	ELDS ARE CLEAR
»»	BOTH THE COSTOP	HRENIC AND CARIOPHRENIC ANGELS ARE CLEAR
»»	BOTH THE HILA ARI	E NORMAL
»»	CARDIAC AND AOR	TIC SHADOWS APPEAR NORMAL
»»	BOTH THE DOMES (OF THE DIAPHRAM ARE NORMAL
»»	VISUALIZED BONY	THORAX IS NORMAL
IMPRESSION	NORMAL	
TMT OR ECHO		
TMT OR ECHO	2D ECHO DONE	
ECG		
ECG	WITHIN NORMAL LI	IMITS
MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT	
RELEVANT PAST HISTORY	NOT SIGNIFICANT	
RELEVANT PERSONAL HISTORY	MARRIED , VEGETA	RIAN
RELEVANT FAMILY HISTORY	NOT SIGNIFICANT	
OCCUPATIONAL HISTORY	JOB	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.87	mts
WEIGHT IN KGS.	98.4	Kgs
BMI	28	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL











CLIENT CODE : C000138361

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro
NEW DELHI, 110092
NEW DELHI, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956
Email : wellness.eastdelhi@srl.in

ABHA NO :

REPORTED :

PATIENT ID:

CLIENT PATIENT ID:

27/02/2023 12:12

PATIENT NAME : RAHUL MALHOTRA

ACCESSION NO : 0028WB00073 AGE : 30 Years SEX : Male DRAWN : RECEIVED : 25/02/2023 08:06

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEND	ER
THYROID GLAND	NOT ENLARGED	
CAROTID PULSATION	NORMAL	
TEMPERATURE	NORMAL	
PULSE	82/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT	
RESPIRATORY RATE	NORMAL	
CARDIOVASCULAR SYSTEM		
BP	130/83	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	S1, S2 HEARD NORMALLY	1
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
SPLEEN	NOT PALPABLE	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	NORMAL	
STINE	NORME	











CLIENT CODE: C000138361

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro
NEW DELHI, 110092
NEW DELHI, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956
Email : wellness.eastdelhi@srl.in

CLIENT PATIENT ID :

PATIENT NAME: RAHUL MALHOTRA PATIENT ID: ACCESSION NO : 0028WB00073 AGE: 30 Years SEX: Male ABHA NO : RECEIVED : 25/02/2023 08:06 **REPORTED** : 27/02/2023 12:12 DRAWN:

REFERRING DOCTOR : SELF

	CELENT FAILENT ID .		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
CONJUNCTIVA	NORMAL		
EYELIDS	NORMAL		
EYE MOVEMENTS	NORMAL		
CORNEA	NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES	NORMAL		
DISTANT VISION LEFT EYE WITHOUT GLASSES	NORMAL		
NEAR VISION RIGHT EYE WITHOUT GLASSES	NORMAL		
NEAR VISION LEFT EYE WITHOUT GLASSES	NORMAL		
COLOUR VISION	NORMAL		
BASIC ENT EXAMINATION			
EXTERNAL EAR CANAL	NORMAL		
TYMPANIC MEMBRANE	NORMAL		
NOSE	NO ABNORMALITY I	DETECTED	
SINUSES	NORMAL		
THROAT	NO ABNORMALITY I	DETECTED	
TONSILS	NOT ENLARGED		
SUMMARY			
RELEVANT HISTORY	NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT		
RELEVANT LAB INVESTIGATIONS	WITHIN NORMAL LI	MITS	
RELEVANT NON PATHOLOGY DIAGNOSTICS	NO ABNORMALITIES	S DETECTED	
REMARKS / RECOMMENDATIONS		FOUND OUT OF THE DIAGNOSTIC PACKAGE RAL PHYSICAL EXAMINATION IS NORMAL."	

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

PATIENT NAME : RAHUL MALHOTRA

	NEW DI NEW DI Tel : 91 CIN - U	I LGF, Nirman Vihar ELHI, 110092 ELHI, INDIA 11591115, Fax : 174899PB1995PLCI wellness.eastdelh	045956	Vihar Metro
			PATIENT ID:	RAHUM09109228A
30 Years	SEX : Male	ABHA NO :		

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN :	RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
ACCESSION NO : 0028WB00073	AGE: 30 Years SEX: Male	ABHA NO :

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicvlates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical,

stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- insulin, ethanol, propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes). The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods,falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

Email : wellness.eastdelhi@srl.in
CIN - U74899PB1995PLC045956
Tel : 9111591115, Fax :
NEW DELHI, INDIA
NEW DELHI, 110092
E-368, LGF, Nirman Vihar, Near Nirman Vihar Metro
SRL Ltd

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
ACCESSION NO : 0028WB00073	AGE: 30 Years SEX: Male	ABHA NO :
PATIENT NAME : RAHUL MALHO	DTRA	PATIENT ID : RAHUM09109228A

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget'''''''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson''''''''s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin.Higher-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers

Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Myasthenia Gravis

Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss). Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic svndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum...Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods. MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd	
E-368, LGF, Nirman Vihar, Near Nirman Vihar	Metro
NEW DELHI, 110092	
NEW DELHI, INDIA	
Tel : 9111591115, Fax :	
CIN - U74899PB1995PLC045956	
Email : wellness.eastdelhi@srl.in	

PATIENT NAME	RAHUL MALHO	TRA	PATIENT ID : RAHUM09109228A
ACCESSION NO :	0028WB00073	AGE: 30 Years SEX: Male	ABHA NO :
DRAWN :		RECEIVED : 25/02/2023 08:06	REPORTED : 27/02/2023 12:12
REFERRING DOCTO	DR: SELF		CLIENT PATIENT ID:
Test Report Stat	us Final	Results	Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN NORMAL SCAN

End Of Report Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
 Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

 Test results cannot be used for Medico legal purposes.
 In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



